Live Breaking News & Updates on Corza Health Inc

Stay updated with breaking news from Corza health inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Takeda Completes Sale of TachoSil® to Corza Health

Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Completes Sale of TachoSil® to Corza Health
February 1, 2021 GMT
OSAKA, Japan (BUSINESS WIRE) Feb 1, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil ® Fibrin Sealant Patch (“TachoSil ® ”) to Corza Health, Inc. (“Corza”) for €350 million.
ADVERTISEMENT
TachoSil ® is a surgical patch trusted by medical professionals globally to deliver safe, fast and reliable bleeding control. Under the terms of the transaction, Corza has acquired the assets and licenses that support the development and commercialization of TachoSil®, while Takeda maintains ownership of the manufacturing facility in Linz, Austria. Takeda has entered into a long-term manufacturing & supply agreement, under which it will continue to exclusively manufacture TachoSil ....

United States , Kazumi Kobayashi , Justine Grosvenor , Christopher Oreilly , Exchange Commission , Corza Health Inc , Takeda Pharmaceutical Company Limited , Takeda Pharmaceutical Company , Pharmaceutical Company Limited , Fibrin Sealant Patch , Corza Health , Fiscal Years , Rare Genetic , Plasma Derived Therapies , Annual Report , Relations Contact , Business Wire , Products And Services , Government Regulations , Ownership Changes , Coronavirus Pandemic , Pharmaceutical Manufacturing , Health Care Industry , Lung Disease , Covid 19 Pandemic , East Asia ,

ZQ Capital Sells Surgical Specialties for About $800 Million

ZQ Capital Sells Surgical Specialties for About $800 Million
Bloomberg
2/1/2021
© Bloomberg
Surgical tools are seen on display in Germany.
(Bloomberg) China-focused private equity firm ZQ Capital sold a U.S. medical device manufacturer to buyout firm GTCR for about $800 million including debt, people familiar with the matter said.
A consortium led by ZQ Capital, founded by a pair of former Barclays Plc and JPMorgan Chase & Co. bankers, and Vivo Capital sold Surgical Specialties Corp., according to a release on Monday, which didn’t give the transaction value.
A representative for ZQ Capital declined to comment on the value. A spokesperson for GTCR didn’t respond to a request for comment. ....

United States , Helge Weiner Trapness , Gregory Lucier , Simon Shen , Corza Health Inc , Life Technologies Corp , Nan Fung Group , Jpmorgan Chase Co , Takeda Pharmaceutical Co , Thermo Fisher Scientific Inc , Surgical Specialties Corp , Barclays Plc , Bloomberg Surgical , Vivo Capital , Aretex Capital , China Orient Asset Management , Fung Shing Investment , Cathay Venture , Corza Health , Surgical Specialties , Tachosil Fibrin Sealant Patch , Corza Medical , Life Technologies , ஒன்றுபட்டது மாநிலங்களில் , கிரெகொரி லூசியர் , சிமோன் ஷென் ,